Drugs / MVA-PCAQ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05617040 | Jan 2023 → Feb 2025 | prostate cancer | Barinthus Biotherapeutics | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-PCAQ | “Biological: MVA-PCAQ” NCT05617040 ↗ |
| Route | Intramuscular | “ChAdOx1-PCAQ 5\*10\^9 vp IM / MVA-PCAQ 5\*10\^7 pfu IM” NCT05617040 ↗ |